Etoposide in Treating Young Patients With Relapsed Ependymoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00278252|
Recruitment Status : Unknown
Verified June 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : January 18, 2006
Last Update Posted : August 7, 2013
RATIONALE: Drugs used in chemotherapy, such as etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well etoposide works in treating young patients with ependymoma.
|Condition or disease||Intervention/treatment||Phase|
|Brain and Central Nervous System Tumors||Drug: etoposide Procedure: conventional surgery||Phase 2|
- Determine the response rate in young patients with relapsing and/or refractory ependymoma treated with a rapid schedule of intravenous etoposide.
- Determine the possibility of second surgery or additional radiotherapy in these patients.
OUTLINE: This is a multicenter study.
Patients receive etoposide IV over 1 hour on days 1-3, 8-10, and 15-17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients whose tumor becomes resectable after courses 3 or 6 undergo surgical resection.
After completion of study treatment, patients are followed periodically for approximately 5 years.
PROJECTED ACCRUAL: At least 14 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||14 participants|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma|
|Study Start Date :||July 2001|
|Estimated Primary Completion Date :||July 2010|
- Response rate by MRI after course 3
- Second surgery or additional radiotherapy in responding patients as assessed by MRI scan after course 3 or 6
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00278252
|Leeds Cancer Centre at St. James's University Hospital||Recruiting|
|Leeds, England, United Kingdom, LS9 7TF|
|Contact: Susan V. Picton, MD 44-11-32-064-985|
|OverallOfficial:||Linda S. Lashford||The Christie NHS Foundation Trust|
|Study Chair:||Susan V. Picton, MD||Leeds Cancer Centre at St. James's University Hospital|